What was the dividend declared by Ipca Laboratories?

The board recommended a dividend of ₹6 per share, representing a 600% payout.

How did the company's margins perform in Q4?

Consolidated EBITDA margins reached 20.52% in Q4, an improvement from the 18.24% reported in the same period last year.

What was the growth in standalone revenue and profit?

Standalone revenue grew by 11% year-on-year, while net profit before exceptional items increased by 35%.

Were there any significant management changes?

No. The board approved the re-appointment of Executive Director Mr. Prashant Godha, which is a routine procedural matter.

Earnings · Pharmaceuticals · Large cap

Ipca Laboratories grows profit 35% as Q4 margins hit 20.52%

The pharmaceutical firm posted an 11% revenue increase for FY26 and declared a dividend of ₹6 per share.

— 1 earlier story on Ipca Laboratories Ltd. →

IPCALAB By Tipsheet Editorial 29 May 2026 · 3:56 PM IST Verify on BSE · NSE

Mkt cap₹38,383 cr

P/E33.64×

ROE10.62%

Debt / eq.0.19

Div yld0.26%

20.52% Consolidated EBITDA margin for Q4 FY26, up from 18.24% a year ago.

What's new

Standalone revenue grew 11% YoY for the full year.
Net profit before exceptional items rose 35% YoY.
Board recommended a dividend of ₹6 per share.

Why this matters

The company delivered higher margins and profit growth, signaling effective cost control in a competitive sector. These results were widely anticipated, leaving little room for surprise in the stock price.

What we're watching

Sustainability of the 20.52% EBITDA margin in upcoming quarters.
Any further commentary on product-mix shifts driving the profit growth.
Market reaction to the dividend payout.

The full read

Ipca Laboratories closed FY26 with a 35% year-on-year increase in net profit before exceptional items. Standalone revenue grew by 11% over the same period.

Consolidated EBITDA margins reached 20.52% in Q4, up from 18.24% a year earlier. The board recommended a dividend of ₹6 per share.

These results were widely anticipated by the market, and the re-appointment of Executive Director Mr. Prashant Godha is a standard procedural step. Given the company's mid-cap status and the broad dissemination of these figures, the market has already factored in the performance. The numbers are strong. The story is routine.

Questions answered

What was the dividend declared by Ipca Laboratories?: The board recommended a dividend of ₹6 per share, representing a 600% payout.
How did the company's margins perform in Q4?: Consolidated EBITDA margins reached 20.52% in Q4, an improvement from the 18.24% reported in the same period last year.
What was the growth in standalone revenue and profit?: Standalone revenue grew by 11% year-on-year, while net profit before exceptional items increased by 35%.
Were there any significant management changes?: No. The board approved the re-appointment of Executive Director Mr. Prashant Godha, which is a routine procedural matter.

Mentioned: Ipca Laboratories · Prashant Godha

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on IPCALAB →

29 May 2026 · 3:56 PM IST Ipca Laboratories grows profit 35% as Q4 margins hit 20.52%
1d ago Ipca Laboratories profit grows 31% in FY26